Evidence map›Paper›PMID 35596003›Full record

ArticleZeitschrift fur Rheumatologie2022

[Gout].

Anne-Kathrin Tausche

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Zeitschrift fur Rheumatologie, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. RepurposingACS omega · 2026
    Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

  • Erratum issued
    2022
5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Anne-Kathrin TauscheMedizinische Klinik III, Rheumatologie, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstr. 74, 01309, Dresden, Deutschland. anne-kathrin.tausche@uniklinikum-dresden.de.
Klinik und Poliklinik für Psychotherapie und Psychosomatik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gout is the most common inflammatory arthritis in men with a rising incidence worldwide. It is a metabolic disease caused by hyperuricemia. Common causes of hyperuricemia, in addition to hereditary reduced renal excretion of urate, include purine over-nutrition, aging, comorbidities and associated medications, some of which increase serum urate levels. The first gout flare represents the signal for deposited urate crystals. If hyperuricemia remains untreated, crystal deposition proceeds and can cause recurrent gout flares, joint destruction and tophi. There is evidence that silent inflammation is ongoing even during asymptomatic stages. Gout patients often exhibit other metabolic, renal and cardiovascular co-morbidities and have higher (cardiovascular) mortality. Therefore, guidelines call for consequent urate lowering strategies to bring serum urate levels to a target at least below 360 µmol/l. The following article summarizes the recent state of knowledge regarding the diagnosis and therapy of gout.

Indexed as

GoutHyperuricemiaGout SuppressantsHumansMaleSymptom Flare UpUric AcidGout SuppressantsUric AcidAllopurinolCrystal arthropathiesFebuxostatGout/comorbiditiesUric acid

Identifiers

PMID35596003
OpenAlexW4280587125

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.